Shane Brown has joined GT Medical Technologies as its chief commercial officer. In this role, he will oversee all aspects of the company’s commercial strategies to drive growth and adoption of …
A once-discarded approach to radiation therapy for brain tumors has re-emerged as a solid secondary treatment for refractory disease. Surgically targeted radiation therapy (STaRT),a form of Cesium-131 brachytherapy, is now …
GT has a number of advantages. Unlike with traditional brachytherapy, the collagen tile provides a buffer around the radiation sources, allowing delivery of the optimal radiation dose while preserving healthy tissue.
GT Medical Technologies, Inc. announced today it was named Company of the Year for Health Products & Services in the 2022 American Business Awards. This honor acknowledges GT Medical Technologies’ pioneering technology GammaTile® Therapy, FDA-cleared for treating newly diagnosed malignant and recurrent brain tumors.
